Bryan Heart

Running trials

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Source

• Recruiting

  OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

  NCT07136012· Phase 3· Source

• Recruiting

  Multi-Site Feasibility Testing of the Ventricular Assist Device Anticipatory Guidance Tool

  NCT06823583· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Source

• Recruiting

  Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

  NCT06909565· Phase 4· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Source

• Active, not recruiting

  TECTONIC CAD IVL IDE Study

  NCT06885177· Source

• Recruiting

  A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

  NCT06112418· Source

• Active, not recruiting

  Amulet™ ADVANCE LAA

  NCT05997446· Source

• Active, not recruiting

  XIENCE Skypoint Large Vessel Post Approval Study

  NCT05423379· Source

• Recruiting

  Assessment of CCM in HF With Higher Ejection Fraction

  NCT05064709· Source

• Recruiting

  Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

  NCT04634240· Source

• Recruiting

  Abbott Vascular Medical Device Registry

  NCT04573660· Source

• Active, not recruiting

  Amplatzer Amulet LAAO vs. NOAC

  NCT04226547· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease5 recruiting
• Heart failure4 recruiting
• Obesity2 recruiting
• Familial hypercholesterolaemia1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Source